American Telemedicine Center, San Juan Health Center, Puerto Rico. Pradnet, Inc., Centro Especializado de Nutrición y Bariatría, Puerto Rico

Size: px
Start display at page:

Download "American Telemedicine Center, San Juan Health Center, Puerto Rico. Pradnet, Inc., Centro Especializado de Nutrición y Bariatría, Puerto Rico"

Transcription

1 List of Principal Investigators Investigator Name Colón, Dr. Gildred Ortíz-Carrasquillo, Dr. Ramón Figueroa Cruz, Dr. Wanda Arakaki, Dr. Richard Liljenquist, Dr. David Klaff, Dr. Leslie Wynne, Dr. Alan Bode, Dr. Bruce Levin, Dr. Philip Rosenstock, Dr. Julio Bergenstal, Dr. Richard Roberts, Dr. Anthony Gerstman, Dr. Murray Davis, Dr. Tim Linjawi, Dr. Sultan Dudas, Dr. Mihaly Vandorfi, Dr. Gyozo Kis-Gombos, Dr. Piroska Jakubowska, Dr. Iwona Szyprowska, Dr. Ewa Pintilei, Dr. Ella Ciomos, Dr. Daniela Guja, Dr. Cristian Veresiu, Dr. Ioan Arefieva, Dr. Elena Ivanova, Dr. Svetlana Pavlova, Dr. Maria Vorobiev, Dr. Sergey De Teresa Parreño, Dr. Luis Durán García, Dr. Santiago Tinahones Madueño, Dr. Francisco Site Name and Country American Telemedicine Center, San Juan Health Center, Puerto Rico Manatí Medical Center, Puerto Rico Pradnet, Inc., Centro Especializado de Nutrición y Bariatría, Puerto Rico University of Hawaii, USA Rocky Mountain Diabetes and Osteoporosis Center, USA Rainier Clinical Research Center, USA Cotton O Neil Diabetes and Endocrinology Center, USA Atlanta Diabetes Associates, USA Model Clinical Research, USA Dallas Diabetes Endocrine Center, USA International Diabetes Center, USA SA Endocrine Research Pty Ltd, Australia Eastern Clinical Research Unit Maroondah Hospital, Australia Fremantle Hospital, School of Medicine and Pharmacology, Australia Coffs Endocrine and Diabetes Services, Australia Bekes Megyei Pandy Kalman Korhaz, Hungary Veszprem Megyei Csolnoky Ferenc Korhaz, Hungary XIII.ker Onkormanyzat Egeszsegugyi Szolgalat, Hungary I Oddz. Diabetologii, Endokrynologii i Chorob Wewnetrznych, Poland NZOZ CenterMed Lublin, Poland SC Consultmed SRL, Romania Cosamext SRL-Centrul Medical Puls, Romania Institutul National de Diabet Nutritie si Boli Metabolice, Romania Spitalul Clinic Judetean de Urgenta Cluj-Napoca, Romania Clinic of St. Elizabeth, Russia Arkhangelsk Regional Clinical Hospital, Russia Moscow Medical Academy, Russia Rostov State Medical University, Russia Clínica Mediterránea de Neurociencias, Spain Hospital Universitario Nuestra Señora de Valme, Unidad de Diabetes Consultas Externas, Spain Centro Especialidades San José Obrero (Barbarela), Hospital Virgen de la Victoria de Malagá España, Spain

2 Supplementary Table 1. LY1 and LY2 Measures of Glycemia at Week 12 LY1 LY2 GL (n=98) (n=97) (n=93) FBG (SMBG), mg/dl Mean ± ± ± 2.7 LS Mean Diff a % CI -1.6, , p-value FSG (Lab), mg/dl Mean ± ± ± 4.1 LS Mean Diff a % CI -8.8, , p-value Daily Mean BG, mg/dl Mean ± ± ± 3.4 LS Mean Diff a % CI , p-value A1C, % Mean 7.1 ± ± ± 0.1 LS Mean Diff a % CI -0.1, , p-value Body Weight, kg Mean 89.8 ± ± ± 2.1 LS Mean Diff % CI -1.4, , p-value Total Hypoglycemia, events/30 d b Mean 1.37 ± ± ± 0.34 Ratio c % CI 0.65, , p-value Nocturnal hypoglycemia, events/30 d b Mean 0.31 ± ± ± 0.12 Ratio c % CI 0.50, , p-value Week 12 data are presented as raw mean ± SE. Treatment differences are reported as LS mean using mixed model repeated measures (MMRM). a LS mean treatment difference is for LY1 minus GL and LY2 minus GL, respectively. b Data reflect overall rate during 12 weeks of treatment. c Ratio is for LY/GL Abbreviations: A1C = hemoglobin A1C, BG = blood glucose, Diff = difference, FBG = fasting blood glucose, LY1 = LY algorithm 1 group, LY2 = LY algorithm 2 group, SE = standard error, SMBG = self-monitored blood glucose.

3 Supplementary Table 2. Change in Antibody Status to LY Baseline Week 12 Follow-up Increased Increased Combined LY (N=195) (n=150) (n=18) 158 (88.8%) 5 (2.8%) (88.3%) 6 (3.5%) -- 2 (1.1%) 6 (3.4%) 7 (3.9%) 2 (1.2%) 12 (7.0%) 0 (0.0%) GL (N=93) (n=75) (n=9) 74 (87.1%) 2 (2.4%) (86.6%) 2 (2.4%) -- 2 (2.4%) 6 (7.1%) 1 (1.2%) 2 (2.4%) 7 (8.5%) 0 (0.0%) Antibody status is categorized as negative and positive at baseline, 12 weeks (treatment period), and 16 weeks (follow-up period). Increased positive is defined as positive at baseline and percent binding is increased by at least 0.5%. The percent is calculated based on the total number of patients with antibody measurement for treatment and follow-up period respectively. Abbreviations: GL = insulin glargine.

4 Supplementary Figure 1. Study design.

5 Supplementary Figure 2. Patient disposition.

6 Supplementary Figure 3. Panel A shows the mean intra-day BG variability (in mg/dl) over the 12- week treatment period. Intra-day BG variability at a visit was quantified as the SD of 8-point SMBG profiles.. Panel B shows the mean inter-day BG variability (in mg/dl) over the 12-week treatment period. Inter-day SMBG variability at a visit was calculated as the SD of daily mean glucose. Solid line with closed circle = insulin glargine, dashed line with closed square = LY BG = blood glucose; SMBG = self-monitored blood glucose; SD = standard deviation. Solid line with closed circle = insulin glargine, dashed line with closed square = LY BG = blood glucose; SMBG = self-monitored blood glucose; SD = standard deviation.

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bergenstal RM, Klonoff DC, Garg SK, et al. -based insulin-pump

More information

Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home

Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home Richard M. Bergenstal 1, David C. Klonoff 2, Bruce W. Bode 3, Satish

More information

Ardhanareeshwarn, Sharada Shah, Parag Kumar, Ajay. Romania: Popa, Amorin Ciomos, Daniela Mistodie, Cristina

Ardhanareeshwarn, Sharada Shah, Parag Kumar, Ajay. Romania: Popa, Amorin Ciomos, Daniela Mistodie, Cristina Participating Investigators: Argentina: Massari, Fabio Sposetti, Georgina Maffei, Laura Starosiliz, David Goycoa, Claudia Perez Mangui, Federico Chertkoff, Alejandro Salzberg, Susana Belgium: Mathieu,

More information

Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations

Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations Diabetes Ther (2017) 8:1265 1296 DOI 10.1007/s13300-017-0328-6 REVIEW Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations Gary Deed. Gary Kilov. Trisha

More information

1. Continuous Glucose Monitoring

1. Continuous Glucose Monitoring 1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection

More information

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2

More information

Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD

Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD International Diabetes Center and Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com

More information

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,

More information

Figure S1. Standard curves for amino acid bioassays. (A) The standard curve for leucine concentration versus OD600 values for L. casei.

Figure S1. Standard curves for amino acid bioassays. (A) The standard curve for leucine concentration versus OD600 values for L. casei. Figure S1. Standard curves for amino acid bioassays. (A) The standard curve for leucine concentration versus OD600 values for L. casei. (B) The standard curve for lysine concentrations versus OD600 values

More information

Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per

Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per APPENDIX 1 Insulin Titration Algorithm Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per day. All subjects will be contacted weekly to review hypoglycemia and adverse

More information

Basal & GLP-1 Fixed Combination Use

Basal & GLP-1 Fixed Combination Use Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

NCT Number: NCT

NCT Number: NCT Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng

More information

Synopsis. None. The trial was started on 13 January 2003 and completed on 02 November Phase 4. Primary Objective:

Synopsis. None. The trial was started on 13 January 2003 and completed on 02 November Phase 4. Primary Objective: Report Body and Synopsis Page: 3 of 53 Synopsis TITLE OF TRIAL A Multinational, Randomised, Controlled, Open-labeled, Parallel Group Evaluation in Terms of Efficacy and Safety of Metformin 1700 mg/day

More information

CURRICULUM VITAE. School of Medicine Cleveland, Ohio; MD, 1970

CURRICULUM VITAE. School of Medicine Cleveland, Ohio; MD, 1970 CURRICULUM VITAE Robert M. Bernstein, MD, FACE Regional Endocrinology Associates, PC Southwest Clinical Research Center 1533 St. Francis Drive, Santa Fe, New Mexico 87505 Phone: (505) 982-2860 Fax: (505)

More information

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly

More information

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female

More information

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lingvay I, Manghi FP, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with type

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Engebretson SP, Hyman LG, Michalowicz BS, et al. The effect of nonsurgical periodontal therapy on hemoglobin A1c levels among persons with type 2 diabetes and chronic periodontitis:

More information

Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016

Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016 Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes Elena Toschi, MD November 12, 2016 Presenter Disclosure Information Elena Toschi, MD No financial disclosure Objectives: Use of CGM

More information

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve

More information

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts

More information

Presented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD

Presented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce

More information

Efficacy/pharmacodynamics: 85 Safety: 89

Efficacy/pharmacodynamics: 85 Safety: 89 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:

More information

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million

More information

CGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117

CGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117 CGM: Continuous Glucose Monitoring Making Sense of It All Objectives Review how to do a time effective interpretation of CGM and insulin pump download data Review how medications, lifestyle, and current

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid

More information

SCIENTIFIC STUDY REPORT

SCIENTIFIC STUDY REPORT PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

The progressive deterioration of pancreatic

The progressive deterioration of pancreatic Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents Prandial premixed (insulin

More information

Gastrointestinal Oncology

Gastrointestinal Oncology 2 nd MD ANDERSON INTERNATIONAL MEETING IN Gastrointestinal Oncology CURRENT PRACTICE AND CONTROVERSIES in the Era of Personalized Medicine e Madrid, 13 th -15 th November, 2019 SCIENTIFIC PROGRAM Meeting

More information

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research

More information

Update on Insulin-based Agents for T2D

Update on Insulin-based Agents for T2D Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment

More information

Convenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy

Convenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy Convenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy Xavier Cos Catalonian Health Institute Barcelona, Spain Stewart B. Harris Western University London, ON, Canada Basal Insulin GLP-1

More information

insulin degludec (Tresiba ) is not recommended for use within NHS Scotland.

insulin degludec (Tresiba ) is not recommended for use within NHS Scotland. insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish

More information

A Practical Approach to the Use of Diabetes Medications

A Practical Approach to the Use of Diabetes Medications A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE

More information

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autistic spectrum disorder:

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

New Guidelines for the Diagnosis of Diabetes Mellitus

New Guidelines for the Diagnosis of Diabetes Mellitus New Guidelines for the Diagnosis of Diabetes Mellitus Joely Straseski, PhD, DABCC, FACB Assistant Professor and Medical Director Endocrinology and Automated Core Laboratory University of Utah and ARUP

More information

Supplementary Material

Supplementary Material Supplementary Material Identification of mir-187 and mir-182 as biomarkers for early diagnosis and prognosis in prostate cancer patients treated with radical prostatectomy Irene Casanova-Salas 1, José

More information

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,

More information

The importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R

The importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R Diabetes Management The importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R Connie A Valdez* 1,2, Leah Fitzgerald 1,2 & Sarah Ziherl Hormachea 2 ABSTRACT

More information

Lilly Diabetes: Pipeline Update

Lilly Diabetes: Pipeline Update Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ

More information

Best Dental Implants Clinics Rating

Best Dental Implants Clinics Rating Helping you make the best choice! Best Dental Implants Clinics Rating Spain 201 Best Dental Implants Clinics 201 Friends are to inspire & to help you make clever decisions! IVF Media & DentalimplantsFriends.com

More information

Figure legends Supplemental Fig.1. Glucose-induced insulin secretion and insulin content of islets. Supplemental Fig. 2.

Figure legends Supplemental Fig.1. Glucose-induced insulin secretion and insulin content of islets. Supplemental Fig. 2. Figure legends Supplemental Fig.. Glucose-induced insulin secretion and insulin content of islets. Insulin secretory responses to.,., and. mm glucose (A) (n = 7-), and the insulin content in the islets

More information

New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011

New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following

More information

Bariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes

Bariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,

More information

Insulin Pumps and Glucose Sensors in Diabetes Management

Insulin Pumps and Glucose Sensors in Diabetes Management Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate

More information

Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM

Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes

More information

SITA 100 mg (n = 378)

SITA 100 mg (n = 378) Supplementary Table 1. Summary of Sulfonylurea Background Therapy at Baseline and During the Treatment Period. Sulfonylurea at baseline, n (%) SITA 100 mg (n = 378) CANA 300 mg (n = 377) Total (N = 755)

More information

Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study

Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study Received: 1 July 2016 Accepted: 3 July 2016 DOI 10.1111/dom.12740 ORIGINAL ARTICLE Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes:

More information

Type 2 Diabetes Mellitus Insulin Therapy 2012

Type 2 Diabetes Mellitus Insulin Therapy 2012 Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration

More information

US M. Adams, Murray, UT R. Fink, La Mesa, CA S. Lerman, Hollywood, FL M. Rendell, Omaha, NE

US M. Adams, Murray, UT R. Fink, La Mesa, CA S. Lerman, Hollywood, FL M. Rendell, Omaha, NE Affinity 1 Study Group US M. Adams, Murray, UT R. Fink, La Mesa, CA S. Lerman, Hollywood, FL M. Rendell, Omaha, NE A. Ahmann, Portland, OR S. Garg, Aurora, CO L. Loman, New Port Richey, FL P. Rosenblit,

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Langdahl BL, Libanati C, Crittenden DB, et

More information

Cohort 2. Age, years 41.0 (10.2) Diabetes duration, years 26.5 (15.8)

Cohort 2. Age, years 41.0 (10.2) Diabetes duration, years 26.5 (15.8) Supplementary Table. Participant characteristics in cohort Cohort Number Sex, Male Female Age, years. (.) Diabetes duration, years.5 (5.) BMI, kg.m. (3.) HbA c, % mmol.mol. (.7) () C-peptide, nmol.l.3

More information

The OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific

The OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific The OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific Affairs,Sysmex 2 OncoBEAM liquid biopsy: circulating tumor DNA (ctdna)

More information

CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION

CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing

More information

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review Wayne H-H Sheu 1,2,3,LinongJi 4,WooJeLee 5, Abdul Jabbar 6,JeongHeeHan 7,ThomasLew 8 * 1 Division

More information

Spectral Analysis of the Blood Glucose Time Series for Automated Diagnosis

Spectral Analysis of the Blood Glucose Time Series for Automated Diagnosis Proceedings of the 1st WSEAS International Conference on SENSORS and SIGNALS (SENSIG '8) Spectral Analysis of the Blood Glucose Time Series for Automated Diagnosis IONELA IANCU *, EUGEN IANCU **, ARIA

More information

Study Code: Date: 27 July 2007

Study Code: Date: 27 July 2007 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Resistance to Thyroid Hormone and Down Syndrome: Coincidental Association or. Genetic Linkage?

Resistance to Thyroid Hormone and Down Syndrome: Coincidental Association or. Genetic Linkage? Page 1 of 6 1 Resistance to Hormone and Down Syndrome: Coincidental Association or Genetic Linkage? (doi: 10.1089/thy.2011-0316) Resistance to Hormone and Down Syndrome: Coincidental Association or Genetic

More information

Supporting Materials for a 31-Day Study of Cobalt(II)chloride Ingestion in Humans: Pharmacokinetics and Clinical Effects

Supporting Materials for a 31-Day Study of Cobalt(II)chloride Ingestion in Humans: Pharmacokinetics and Clinical Effects Supporting Materials for a 31- Study of Cobalt(II)chloride Ingestion in Humans: Pharmacokinetics and Clinical Effects Brent L. Finley a, Kenneth M. Unice b, Brent D. Kerger c, Joanne M. Otani a, Dennis

More information

ADAG Study Group Data Links A1C Levels with Empirically Measured Blood Glucose Values - New Treatment Guidelines Will Now be Needed

ADAG Study Group Data Links A1C Levels with Empirically Measured Blood Glucose Values - New Treatment Guidelines Will Now be Needed 529638DSTXXX10.1177/1932296814529638Journal of Diabetes Science and TechnologyKlonoff research-article2014 Editorial ADAG Study Group Data Links A1C Levels with Empirically Measured Blood Glucose Values

More information

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

UKPDS: Over Time, Need for Exogenous Insulin Increases

UKPDS: Over Time, Need for Exogenous Insulin Increases UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin

More information

Original. Shizuka Kaneko 1), Tomonori Oura 2), Akiko Matsui 2), Tomotaka Shingaki 2) and Masakazu Takeuchi 2)

Original. Shizuka Kaneko 1), Tomonori Oura 2), Akiko Matsui 2), Tomotaka Shingaki 2) and Masakazu Takeuchi 2) 2017, 64 (12), 1165-1172 Original Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin

More information

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better

More information

LION-HEART. Levosimendan Intermittent administration in Outpatients: effects on Natriuretic peptides in advanced chronic HEART failure

LION-HEART. Levosimendan Intermittent administration in Outpatients: effects on Natriuretic peptides in advanced chronic HEART failure LION-HEART Levosimendan Intermittent administration in Outpatients: effects on Natriuretic peptides in advanced chronic HEART failure Multicentre, randomized, double-blind, parallel group, placebo-controlled

More information

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009 Design and Analysis of a Cancer Prevention Trial: Plans and Results Matthew Somerville 09 November 2009 Overview Objective: Review the planned analyses for a large prostate cancer prevention study and

More information

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company: These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov

More information

9/23/09. What are the key components of preoperative, intraoperative, & postoperative care of diabetes management? Rebecca L. Sturges, M.D.

9/23/09. What are the key components of preoperative, intraoperative, & postoperative care of diabetes management? Rebecca L. Sturges, M.D. RMHS Perioperative Summit: Perioperative Diabetes Management Rebecca L. Sturges, M.D. Oct 6, 2009 Mrs. B was referred by her orthopedic surgeon to your preoperative clinic to discuss medical management

More information

Supplementary Data. Correlation analysis. Importance of normalizing indices before applying SPCA

Supplementary Data. Correlation analysis. Importance of normalizing indices before applying SPCA Supplementary Data Correlation analysis The correlation matrix R of the m = 25 GV indices calculated for each dataset is reported below (Tables S1 S3). R is an m m symmetric matrix, whose entries r ij

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure

More information

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes https://helda.helsinki.fi Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Riddle, Matthew C. 2016-04-01 Riddle, M C, Bolli, G B,

More information

Reconstructive Oral and Maxillofacial Surgery

Reconstructive Oral and Maxillofacial Surgery Reconstructive Oral and Maxillofacial Surgery Carlos Navarro Vila Editor Reconstructive Oral and Maxillofacial Surgery Editor Carlos Navarro Vila Hospital General Universitario Gregorio Marañón Madrid

More information

iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L

iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L Diabetes Ther (2018) 9:373 382 https://doi.org/10.1007/s13300-017-0336-6 BRIEF REPORT iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post

More information

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY) Page 1 of 41 ID: 10935 Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY) NCT00494013 Close Protocol Registration and Results Preview Comparison of Two Basal Insulins for Patients

More information

Novel Formulations to Modify Mealtime Insulin Kinetics

Novel Formulations to Modify Mealtime Insulin Kinetics Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees

More information

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL) PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to

More information

Supplementary Online Content 2. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on

Supplementary Online Content 2. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on Supplementary Online Content 2 Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated

More information

Making Sense of Glucose Monitoring. My Journey with Glucose Monitoring Over the Last 37 Years 8/7/2017

Making Sense of Glucose Monitoring. My Journey with Glucose Monitoring Over the Last 37 Years 8/7/2017 HSW1 Disclosure to Participants Making Sense of Glucose Monitoring Alison B. Evert, MS, RD, CDE UW Neighborhood Clinics UW Medicine Seattle, WA Conflict of Interest (COI) and Financial Relationship Disclosures:

More information

Akio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka

Akio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial

More information

ORIGINAL ARTICLE. Qing SU, 1 Chao LIU, 3 Hongting ZHENG, 4 Jun ZHU, 5 Peng Fei LI, 2 Lei QIAN 2 and Wen Ying YANG 6

ORIGINAL ARTICLE. Qing SU, 1 Chao LIU, 3 Hongting ZHENG, 4 Jun ZHU, 5 Peng Fei LI, 2 Lei QIAN 2 and Wen Ying YANG 6 Journal Journal of Diabetes of Diabetes 9 (2017), (2016) 575 585 ORIGINAL ARTICLE Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes

More information

Application of the Diabetes Algorithm to a Patient

Application of the Diabetes Algorithm to a Patient Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent

More information

Mobile communications devices, including mobile

Mobile communications devices, including mobile DIABETES TECHNOLOGY & THERAPEUTICS Volume 17, Number 8, 2015 DOI: 10.1089/dia.2014.0407 ORIGINAL ARTICLE Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical

More information

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set

More information

CTAF Overview. Agenda. Evidence Review. Insulin Degludec (Tresiba, Novo Nordisk) for the Treatment of Diabetes

CTAF Overview. Agenda. Evidence Review. Insulin Degludec (Tresiba, Novo Nordisk) for the Treatment of Diabetes CTAF Overview Insulin Degludec (Tresiba, Novo Nordisk) for the Treatment of Diabetes February 12, 2016 Core program of the Institute for Clinical and Economic Review (ICER) Goal: Help patients, clinicians,

More information

ERECTILE DYSFUNCTION DIAGNOSIS

ERECTILE DYSFUNCTION DIAGNOSIS ERECTILE DYSFUNCTION DIAGNOSIS Head of Andrology and Sexual Medicine Dep.of Urology and Nefrology Hospital Virgen del Rocío ANDROMEDI. Sexual Medicine SEVILLA. SPAIN General Secretary ESSM Natalio Cruz

More information

Artificial Pancreas Device System (APDS)

Artificial Pancreas Device System (APDS) Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER

More information

What Are the Targets in CKD-MBD?

What Are the Targets in CKD-MBD? Knowledge Exchange 2016 Paris, France, September 30, 2016 Date of preparation: Nov 2016 Item job code: INTSP/C-ANPROM/FOS/16/0025 Cristina Ortiz Jorge B Cannata-Andía Bone and Mineral Research Unit Hospital

More information

Clinical Value and Evidence of Continuous Glucose Monitoring

Clinical Value and Evidence of Continuous Glucose Monitoring Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals

More information

P.Venkatesan Chief Operating Officer

P.Venkatesan Chief Operating Officer Diabetopaedia. com Meeting the challenges of Providing Information for Doctors, Patients other and Health-Carers in Diabetes. by P.Venkatesan Chief Operating Officer DIABETOPAEDIA DOT COM PVT. LTD. venkat@diabetopaedia.com

More information

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard

More information

5/15/2018 DISCLOSURE OBJECTIVES. FLORIDA HOSPITAL ORLANDO Not for profit organization Acute care medical center 1,368 licensed beds BACKGROUND

5/15/2018 DISCLOSURE OBJECTIVES. FLORIDA HOSPITAL ORLANDO Not for profit organization Acute care medical center 1,368 licensed beds BACKGROUND DISCLOSURE PHARMACIST DIRECTED MANAGEMENT OF GLUCOCORTICOID INDUCED HYPERGLYCEMIA AT A LARGE COMMUNITY HOSPITAL Jill Zaccardelli, PharmD PGY1 Pharmacy Resident Florida Hospital Orlando Jill.Zaccardelli@flhosp.org

More information